- $192.28m
- $125.69m
- $129.42m
Niagen Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Niagen Bioscience Q2 net sales fall, missing estimates
Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
Niagen rises after U.S., EU rare disease designations for drug candidate
Brief: NARB Recommends Niagen Modify/Discontinue Certain Tru Niagen Nad+ Dietary Supplement Claims
Niagen Bioscience Q1 sales rise 3%, beat estimates
Brief: Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Brief: Niagen Bioscience Adds Olympia Pharmaceuticals To 503B Compounding Partner Network For Niagen Plus™
Brief: Niagen Bioscience Surpasses 300 External Research Agreements From Leading Global Institutions On Niagen®, Contributing To 45 Published Clinical Studies
Niagen Bioscience Q4 net sales rise
Brief: Niagen Bioscience To Streamline Operations With The Sale Of Chromadex Reference Standards Business To LGC
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
Niagen Bioscience rises on U.S. patent for injectable NAD+ booster
Brief: Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside
Brief: Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen